Allergy Therapeutics (LSE:AGY) — Market Cap & Net Worth
Market Cap & Net Worth: Allergy Therapeutics (AGY)
Allergy Therapeutics (LSE:AGY) has a market capitalization of $7.66 Million (GBX62.95 Billion) as of May 4, 2026. Listed on the LSE stock exchange, this UK-based company holds position #27491 globally and #389 in its home market, demonstrating a -5.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Allergy Therapeutics's stock price GBX10.25 by its total outstanding shares 6141439951 (6.14 Billion). Analyse Allergy Therapeutics operating cash flow efficiency to see how efficiently the company converts income to cash.
Allergy Therapeutics Market Cap History: 2015 to 2026
Allergy Therapeutics's market capitalization history from 2015 to 2026. Data shows change from $22.04 Million to $7.66 Million (-9.21% CAGR).
Index Memberships
Allergy Therapeutics is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.14 Million | 0.83% | #25 of 722 |
Weight: Allergy Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Allergy Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Allergy Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
Allergy Therapeutics's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.60 Million | $48.51 Million | -$13.07 Million | 0.32x | N/A |
| 2017 | $21.30 Million | $64.14 Million | -$2.48 Million | 0.33x | N/A |
| 2018 | $10.18 Million | $68.35 Million | -$7.53 Million | 0.15x | N/A |
| 2019 | $7.66 Million | $73.72 Million | $3.47 Million | 0.10x | 2.21x |
| 2020 | $12.42 Million | $78.20 Million | $7.06 Million | 0.16x | 1.76x |
| 2021 | $24.66 Million | $84.33 Million | $2.89 Million | 0.29x | 8.54x |
| 2022 | $4.67 Million | $72.77 Million | -$13.78 Million | 0.06x | N/A |
| 2023 | $1.87 Million | $59.59 Million | -$43.07 Million | 0.03x | N/A |
| 2024 | $4.86 Million | $55.20 Million | -$40.22 Million | 0.09x | N/A |
| 2025 | $8.22 Million | $55.04 Million | -$40.13 Million | 0.15x | N/A |
Competitor Companies of AGY by Market Capitalization
Companies near Allergy Therapeutics in the global market cap rankings as of May 4, 2026.
Key companies related to Allergy Therapeutics by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Allergy Therapeutics Historical Marketcap From 2015 to 2026
Between 2015 and today, Allergy Therapeutics's market cap moved from $22.04 Million to $ 7.66 Million, with a yearly change of -9.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX7.66 Million | -6.82% |
| 2025 | GBX8.22 Million | +69.23% |
| 2024 | GBX4.86 Million | +160.00% |
| 2023 | GBX1.87 Million | -60.00% |
| 2022 | GBX4.67 Million | -81.06% |
| 2021 | GBX24.66 Million | +98.50% |
| 2020 | GBX12.42 Million | +62.20% |
| 2019 | GBX7.66 Million | -24.77% |
| 2018 | GBX10.18 Million | -52.19% |
| 2017 | GBX21.30 Million | +36.53% |
| 2016 | GBX15.60 Million | -29.24% |
| 2015 | GBX22.04 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Allergy Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.66 Million USD |
| MoneyControl | $7.66 Million USD |
| MarketWatch | $7.66 Million USD |
| marketcap.company | $7.66 Million USD |
| Reuters | $7.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more